Affect Therapeutics offers a smartphone app that integrates contingency management with virtual therapy to support individuals recovering from drug and alcohol addiction. The platform provides financial incentives for healthy behaviors, along with personalized care and resources to facilitate lasting lifestyle changes.

AviadoBio develops gene therapies utilizing a neuroanatomy-led approach to deliver treatments directly to the central nervous system for patients with frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company addresses the lack of effective therapies for these neurodegenerative disorders by maximizing therapeutic potential to potentially halt or reverse disease progression.

Closed Loop Medicine develops personalized digital healthcare solutions that integrate dose-optimized drug therapy with digital therapeutics to enhance treatment adherence and patient outcomes. The platform addresses the inefficiencies of traditional healthcare delivery, which often leads to suboptimal management of chronic conditions and increased costs for payors.

Cumulus Neuroscience has developed a medical-grade platform that integrates at-home EEG monitoring with tablet-based cognitive assessments to collect longitudinal data on brain health. This technology addresses the challenges of late diagnosis and ineffective monitoring in neurodegenerative diseases and psychiatric disorders, facilitating more efficient clinical trials and improving therapy delivery.

The startup develops multispecific antibodies that enhance the functionality of innate and adaptive immune cells, providing targeted engagement for improved therapeutic outcomes. This approach addresses the limitations of existing therapies by offering a more effective means to direct immune responses against diseases.

GlycoEra develops biologic therapeutics that selectively degrade pathogenic circulating proteins, such as autoantibody IgG4, to treat autoimmune diseases. Its platform enables rapid, deep, and specific removal of disease‑driving extracellular targets while preserving overall immune function. This precision immunology approach aims to allow earlier intervention, improve patient outcomes, and reduce reliance on broad immunosuppression.

Hillstar Bio develops precision immunotherapies that selectively deplete pathogenic immune‑cell subsets to reset the immune system in autoimmune diseases. By engineering antibodies that target disease‑specific genetic markers, its candidates aim to spare healthy cells, reduce adverse effects, and enable less frequent dosing compared to broad immunosuppression. The lead program, HSB‑101, targets TRBV9+ T cells for axial spondyloarthritis and related HLA‑B27‑mediated conditions, with preclinical work advancing toward a Phase 1 trial.

Ikarovec is a pre-clinical gene therapy company developing targeted treatments for diabetic macular edema and other common eye diseases through gene transfer techniques that introduce therapeutic DNA into ocular cells. This approach aims to provide long-lasting benefits with a single injection, reducing the need for frequent treatments and addressing the risk of vision loss.

Maxion Therapeutics utilizes its patented KnotBody® technology to develop engineered antibody therapeutics targeting ion channel and GPCR-driven diseases, which are often inadequately treated by existing small molecule drugs. The company focuses on creating safe, effective, and long-acting treatments for chronic pain, autoimmune disorders, and cardiovascular diseases, addressing a significant unmet medical need for over 1.8 billion patients worldwide.

Ozlo Sleep develops specialized audio technology in the form of Sleepbuds, designed to enhance sleep quality by masking disruptive noises and promoting relaxation. These earbuds address the challenge of sleep disturbances without medication, providing users with a non-invasive solution to improve their sleep rituals.

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza. This approach aims to deliver immediate and sustained protection against severe viral disease, particularly for immunocompromised populations. The LAAbs provide protection independent of the patient's ability to mount a maximal response to seasonal vaccines.

T-Cypher Bio develops T-cell receptor-based therapeutics that utilize proprietary target screening libraries to identify functionally defined T-cell clones from disease tissues, specifically for solid tumors and other immune-mediated diseases. This approach enables healthcare providers to create tailored cell therapies that address the limitations of existing cancer treatments by targeting a broader range of tumor-specific antigens.

Tribune Therapeutics is developing novel medicines that target key CCN protein family members to inhibit the pro-fibrotic signaling pathways responsible for fibrosis across various tissues. Their lead candidate, TRX-44, effectively blocks fibrotic signaling in preclinical models of lung and kidney fibrosis, addressing the critical issue of organ scarring and dysfunction.

The startup develops small molecule therapeutics that promote remyelination to repair damaged myelin sheaths in patients with multiple sclerosis. Their therapies aim to reverse the debilitating effects of the disease, enhancing neurological function and quality of life for affected individuals.